We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-14.07%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.34B
AUM Growth
-$421M
Cap. Flow
+$11.7M
Cap. Flow %
0.5%
Top 10 Hldgs %
40.93%
Holding
221
New
9
Increased
52
Reduced
52
Closed
18

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$15.4M
2
MDT icon
Medtronic
MDT
+$13.3M
3
UNH icon
UnitedHealth
UNH
+$8.16M
4
ISRG icon
Intuitive Surgical
ISRG
+$7.42M
5
PFE icon
Pfizer
PFE
+$7.12M

Top Sells

Rank Stock Value
1
AET
Aetna Inc
AET
+$17M
2
AZN icon
AstraZeneca
AZN
+$11.3M
3
IDXX icon
Idexx Laboratories
IDXX
+$10.4M
4
VTRS icon
Viatris
VTRS
+$8.21M
5
OHI icon
Omega Healthcare
OHI
+$6.92M

Sector Composition

Rank Sector Weight
1 Healthcare 94.39%
2 Real Estate 2.48%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACAD icon
201
Acadia Pharmaceuticals
ACAD
$4.55B
– –
-93,689
Closed -$1.95M
ARGX icon
202
argenx
ARGX
$54.6B
– –
-15,188
Closed -$1.15M
ASRT
203
DELISTED
Assertio
ASRT
– –
-17
Closed -$6K
HSIC icon
204
Henry Schein
HSIC
$9.7B
– –
-40,035
Closed -$2.67M
RGEN icon
205
Repligen
RGEN
$7.03B
– –
-38,700
Closed -$2.15M
RMR icon
206
The RMR Group
RMR
$333M
– –
-5,323
Closed -$494K
TBPH icon
207
Theravance Biopharma
TBPH
$873M
– –
-8,083
Closed -$264K
YARW
208
Yarrow Bioscience, Inc. Common Stock
YARW
$22M
– –
-7
Closed -$244K
RVNC
209
DELISTED
Revance Therapeutics, Inc.
RVNC
– –
-77,919
Closed -$1.94M
LUMO
210
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-22,781
Closed -$490K
CBAY
211
DELISTED
Cymabay Therapeutics
CBAY
– –
-169,962
Closed -$1.88M
XENT
212
DELISTED
Intersect ENT, Inc
XENT
– –
-8,356
Closed -$240K
TLGT
213
DELISTED
Teligent, Inc
TLGT
– –
-10,146
Closed -$401K
HZNP
214
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-162,900
Closed -$3.19M
TSRO
215
DELISTED
TESARO, Inc.
TSRO
– –
-94,970
Closed -$3.71M
ECYT
216
DELISTED
Endocyte, Inc. Common Stock
ECYT
– –
-41,980
Closed -$746K
ESRX
217
DELISTED
Express Scripts Holding Company
ESRX
– –
-53,250
Closed -$5.06M
AET
218
DELISTED
Aetna Inc
AET
– –
-83,637
Closed -$17M
5 6 7 8
9

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2018 Portfolio in Review

As of Q4 2018, Tekla Capital Management held 221 positions worth $2.34B, down 15% from $2.76B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Tekla Capital Management's Q4 2018 filing shows 9 new, 52 increased, 52 reduced and 18 closed positions. Its largest new stake was Wellcare Health Plans, Inc.: 13,000 shares worth $3.07M. The largest sale was Aetna Inc, an estimated $17M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 94% a quarter earlier, followed by Real Estate and Financials.

  • Tekla Capital Management's largest Q4 2018 buy was Wellcare Health Plans, Inc.: 13,000 shares worth $3.07M.
  • Tekla Capital Management added most to Bristol-Myers Squibb in Q4 2018, an estimated $15.4M increase.
  • Tekla Capital Management's biggest Q4 2018 reduction was AstraZeneca, cutting an estimated $11.3M.
  • Tekla Capital Management fully exited Aetna Inc in Q4 2018, selling an estimated $17M.
  • Tekla Capital Management's ten largest holdings make up 41% of its $2.34B portfolio in Q4 2018.
  • Tekla Capital Management opened 9 new positions and closed 18 in Q4 2018.
  • Tekla Capital Management's portfolio value fell 15% quarter-over-quarter to $2.34B.

Based on Tekla Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.